ClinicalTrials.gg
RecruitingNCT05928728COLFIBUpdated Feb 28, 2024

The COLchicine and Atrial FIBrillation Trial

A Phase 3 interventional study of Colchicine and Placebo in Atrial Fibrillation, sponsored by Herlev and Gentofte Hospital. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Herlev and Gentofte Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing colchicine in Atrial Fibrillation — 4 open to participants now, 5 under way, 3 of them phase 3. Colchicine · Atrial Fibrillation.

Planned enrollment
2nd of 22
500 · median 236
Started
2023
the only one that year
Phase 3
13 of 22
3 open now
Registered
17th of 22
by date
Lead sponsor
1 of 22
Herlev and Gentofte Hospital

Among the 22 studies testing colchicine in Atrial Fibrillation, this one is the 2nd largest by planned enrollment, is the only one that started in 2023, is one of 13 in phase 3, and was the 17th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

4 of the 22 studies testing colchicine in Atrial Fibrillation are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About colchicine

Colchicine: first FDA approval 1961 (COLBENEMID), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing colchicine in Atrial Fibrillation, or all of them as a file.
02

Study summary

The purpose of this study to investigate the effects of colchicine on atrial fibrillation recurrence and vascular and cardiac function in patients with atrial fibrillation.

Read the detailed description

The study is an investigator-initiated, prospective, double-blind, placebo-controlled, randomized clinical trial investigating the effects of colchicine in patients with atrial fibrillation (AF). The study population will consist of approximately 500 patients aged 18 years and above with a diagnosis of paroxysmic or persistent AF with a successful outcome of cardioversion. Patients will be randomized to either low-dose colchicine treatment (0,5 mg once daily) or placebo. Treatment will continue for 12 months. Patients will be assessed by measurement of time to first admission with AF (Electro Cardio Gram (ECG) confirmed), echocardiography, cardiac Magnetic Resonance Imaging (MRI), and blood samples at baseline and after 6 + 12 months.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Living address in the Capital Region of Denmark
  2. Age > 18
  3. Diagnosed with paroxysmic/persistent AF.
  4. Planned or acute admission for cardioversion of AF with successful outcome.
  5. Female participants should either not be of , defined as for at least 1 year or surgically sterile, or is of childbearing potential and practicing one of the following methods of throughout the study and for 30 days after study completion: Hormonal contraception (oral contraceptives, contraceptive implant, injectable birth control, contraceptive patch, or vaginal ring) or intrauterine device
  6. Participants will have given written, and are able and willing to comply with the requirements of the study protocol.
  7. Optimal background therapy (in relation to comorbidities and development of heart failure / thromboembolic event) for AF as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  1. Colchicine treatment for another cause, e.g. gout
  2. Allergy/ to colchicine
  3. Uncontrolled hypertension (systolic BP >180 mmHg or diastolic BP >110 mmHg)
  4. History of of any organ system excluding a successfully treated non- cutaneous squamous cell or basal cell carcinoma, localized prostate cancer and/or localized carcinoma in situ of the cervix
  5. Cirrhosis, chronic active hepatitis or other severe hepatic disease
  6. Hemodialysis
  7. Estimated (eGFR) \< 60 mL/min/1.73 m2
  8. Systemic treatment with moderate or strong cytochrome P450 3A4 () inhibitors or P-glycoprotein inhibitors (list in Appendix 1)
  9. Permanent AF
  10. Female participants who are pregnant, lactating, or considering becoming pregnant during the study or for 6 months after study completion
  11. Significant drug or alcohol abuse during the last year
  12. Current use of or plans to initiate chronic systemic therapy during the study (topical or inhaled steroids are allowed)
  13. Planned ablation procedure as treatment for AF
  14. If cardiovascular surgery or ablation has been done the past three months prior to inclusion.
  15. Chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis) or chronic diarrhea
  16. Use of other drugs within 30 days of the time of enrollment
  17. Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study.
  18. Suspected AF, confirmed with , at time of inclusion and randomization
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Colchicine

    Drug: Colchicine

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Colchicine 0.5 mg once daily

  • DrugPlacebo

    Placebo once daily

06

What researchers measure

Primary outcomes

  1. Between-group difference in change in time to first AF admission measured in days

    Time frame: 12 months

Secondary outcomes

  1. Between-group difference in change in accumulated number of readmissions for symptomatic AF

    Time frame: 12 months

  2. Between-group difference in change in Left Atrial Volume (LAV) assessed by echocardiography

    Time frame: 12 months

  3. Between-group difference in change in Atrial Fibrillation Effect On Quality-Of-Life Questionnaire (AFEQT) score

    Score of 0 being the worst outcome and score of 100 being the best outcome

    Time frame: 12 months

Other outcomes

  1. Between-group difference in change in plasma concentration of high sensitivity C-Reactive Protein (hs-CRP)

    Time frame: 12 months

  2. Between-group difference in change in plasma concentration of high sensitivity Troponin I (hs-TnI)

    Time frame: 12 months

  3. Between-group difference in change in Left Ventricle (LV) septal wall thickness assessed by echocardiography

    Time frame: 12 months

  4. Between-group difference in change in LV mass index assessed by echocardiography

    Time frame: 12 months

  5. Between-group difference in change in LV posterior wall thickness assessed by echocardiography

    Time frame: 12 months

  6. Between-group difference in change in Left Ventricle Ejection Fraction (LVEF) assessed by echocardiography

    Time frame: 12 months

  7. Between-group difference in change in E/A ratio assessed by echocardiography

    Time frame: 12 months

  8. Between-group difference in change in e' assessed by echocardiography

    Time frame: 12 months

  9. Between-group difference in change in E/e' ratio assessed by echocardiography

    Time frame: 12 months

  10. Between-group difference in change in Global Longitudinal Strain (GLS) assessed by echocardiography

    Time frame: 12 months

  11. Between-group difference in change in aortic distensibility assessed by echocardiography

    Time frame: 12 months

  12. Between-group difference in change in aortic strain assessed by echocardiography

    Time frame: 12 months

  13. Between-group difference in change in LV septal wall thickness assessed by cardiac MRI

    Time frame: 12 months

  14. Between-group difference in change in LV posterior wall thickness assessed by cardiac MRI

    Time frame: 12 months

  15. Between-group difference in change in LVEF assessed by cardiac MRI

    Time frame: 12 months

  16. Between-group difference in change in myocardial fibrosis assessed by cardiac MRI

    Time frame: 12 months

  17. Between-group difference in change in myocardial inflammation assessed by cardiac MRI

    Time frame: 12 months

  18. Between-group difference in change in plasma concentration of Tumor Necrosis Factor alpha (TNF-α)

    Time frame: 12 months

  19. Between-group difference in change in plasma concentration of pro Brain Natriuretic Peptide (pro-BNP)

    Time frame: 12 months

  20. Between-group difference in change in accumulated number of cardiovascular-related hospital visits

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jun 2026, 35 months after the start.

Of 62 non-industry phase 3 interventional studies under Atrial Fibrillation, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 73. This study's planned 35 months is below that.

Counting every sponsor, half of 83 studies reached it within 42 months; a quarter within 32 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2023
First posted
Jul 3, 2023
StartActual
Jul 3, 2023
Primary completionEst.
Jun 14, 2026
CompletionEst.
Nov 1, 2028
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05928728
Lead sponsor
Herlev and Gentofte Hospital
Responsible party
Adam Femerling Langhoff (Principal Investigator, Herlev and Gentofte Hospital) — Principal investigator
First posted
Jul 3, 2023
Start date
Jul 3, 2023
Primary completion
Jun 14, 2026 (estimated)
Completion
Nov 1, 2028 (estimated)
Last update
Feb 28, 2024

Study contacts

Adam Femerling Langhoff, M.D.
Contact
adam.femerling.langhoff@regionh.dk
+4522552317
Tor Biering-Sørensen, MD, PhD, MPH
Contact
tor.biering-soerensen@regionh.dk
+4528933590
Adam Femerling Langhoff, M.D.
principal investigator · Herlev and Gentofte Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Colchicine

Start the discussion